Opticyte
Opticyte is a medical device company focused on transforming the standard of care for sepsis and other causes of organ failure through real-time oxygen monitoring. Their VitalO₂ device is the world's only cell O₂ monitor, offering accurate measurements for all skin tones, addressing a critical disparity in current pulse oximetry technology. Recognized by the FDA as a Breakthrough Device, VitalO₂ provides definitive, continuous, and actionable insights to clinicians for early detection and treatment. The company has secured significant non-dilutive funding and is currently raising crowdfunding. The team comprises experienced engineers, regulatory experts, and medical professionals, including founders with deep expertise in optical spectroscopy.
Opticyte
Opticyte is a medical device company focused on transforming the standard of care for sepsis and other causes of organ failure through real-time oxygen monitoring. Their VitalO₂ device is the world's only cell O₂ monitor, offering accurate measurements for all skin tones, addressing a critical disparity in current pulse oximetry technology. Recognized by the FDA as a Breakthrough Device, VitalO₂ provides definitive, continuous, and actionable insights to clinicians for early detection and treatment. The company has secured significant non-dilutive funding and is currently raising crowdfunding. The team comprises experienced engineers, regulatory experts, and medical professionals, including founders with deep expertise in optical spectroscopy.
TL;DR
Headquarters: Seattle, WA
Founded: 2016
Core product: VitalO2 Cell O2 patient monitor (noninvasive cellular oxygenation + pulse oximetry)
Regulatory highlight: FDA Breakthrough Device Designation
Team size: 8 employees (reported)
Funding mix: Non-dilutive grants, seed/angel/private investments, crowdfunding
Company Overview
Problem Domain
Early detection and monitoring of organ failure (including sepsis and trauma) via improved oxygenation measurement.
Founded
2016
Industry
Medical devices; health technology
Funding Track Record
Non-dilutive grant funding (NIH) reported as early funding
Non-dilutive grant funding (NSF)
Seed round listed with corporate/strategic investor participation
Listed as a non-equity assistance funding event
StartEngine campaign raised >$100,000 in one week; company reports additional angel investments including FBomb Angels (Dec 2024)
Investor Signal
“Mix of non-dilutive grants, strategic/corporate investors (StarFish Medical), accelerator support (MedTech Innovator), angel investors (e.g., FBomb Angels), and crowdfunding”